ABBV · Earnings call · 2026Q3T · Full report

Operating Expense Trends

AbbVie Inc. · 2026-10-30 · Importance 50 · Surprise 42

Third-quarter adjusted R&D expense was 13.9% of sales, while adjusted SG&A expense was 21.2% of sales. For full-year 2026, AbbVie forecast adjusted R&D expense of approximately $9.8 billion and adjusted SG&A expense of approximately $14.5 billion. Acquired IPR&D expense reduced third-quarter adjusted EPS by $0.11 and lowered the adjusted operating margin by 1.2 percentage points; the full-year operating-margin impact from acquired IPR&D through the third quarter was approximately 1.8 percentage points.